Aims : to present the latest approaches to preventing development of active tuberculosis through treatment of latent disease; to understand the role of the fungal microbiome and its effect on lung immunity; to prevent nosocomial spread of non-tuberculous mycobacteria within the cystic fibrosis clinic, and nosocomial pneumonias, including ventilator-associated pneumonia, by adherence to evidence-based guidelines;